REGN
Regeneron Pharmaceuticals Inc.
$701.42
-$5.64(-0.80%)
62
Overall
80
Value
50
Tech
57
Quality
Market Cap
$61.26B
Volume
728.88K
52W Range
$476.49 - $821.11
Target Price
$878.93
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $4.9B | $5.9B | $6.7B | $6.6B | $8.5B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B | ||
| Total Revenue | $4.9B | $5.9B | $6.7B | $6.6B | $8.5B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $194.6M | $202.5M | $254.1M | $402.8M | $1.1B | $2.4B | $1.6B | $1.8B | $2.0B | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $4.7B | $5.7B | $6.5B | $6.2B | $7.4B | $13.6B | $10.6B | $13.1B | $14.2B | $14.3B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $3.2B | $3.4B | $3.7B | $3.6B | $3.8B | $4.6B | $5.6B | $7.1B | $8.1B | $8.5B | ||
| Research & Development | $2.1B | $2.1B | $2.2B | $2.5B | $2.7B | $2.9B | $3.6B | $4.4B | $5.1B | $5.9B | ||
| Research Expense | $2.1B | $2.1B | $2.2B | $2.5B | $2.7B | $2.9B | $3.6B | $4.4B | $5.1B | $5.9B | ||
| Selling, General & Administrative | $1.2B | $1.3B | $1.6B | $1.3B | $1.3B | $1.8B | $2.1B | $2.6B | $3.0B | $2.7B | ||
| General & Administrative Expenses | $1.2B | $1.3B | $1.6B | $1.3B | $1.3B | $1.8B | $2.1B | $2.6B | $3.0B | $2.7B | ||
| Depreciation & Amortization | $104.7M | $145.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $104.7M | $145.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Amortization | -- | -- | -- | $14.4M | $14.4M | $14.4M | $930.0M | $1.1B | $1.2B | -- | ||
| Other Operating Expenses | $-45.6M | $-49.0M | $-51.4M | $-209.2M | $-280.4M | $-45.6M | $-89.9M | $-2.1M | $53.4M | $-10.0M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $1.3B | $2.1B | $2.5B | $2.2B | $3.6B | $8.9B | $4.7B | $4.0B | $4.0B | $3.6B | ||
| EBITDA | $1.4B | $2.2B | $2.7B | $2.7B | $4.1B | $9.7B | $5.3B | $4.7B | $5.3B | $5.8B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | $25.1M | $28.2M | $30.2M | $56.9M | $57.3M | $59.4M | $73.0M | $55.2M | $43.8M | ||
| Interest Income Operating | -- | -- | -- | -- | -- | $45.8M | -- | -- | -- | -- | ||
| Intinc | $-7.2M | $-25.1M | -- | -- | -- | -- | -- | -- | $711.4M | -- | ||
| Net Non-Operating Interest Income/Expense | $-7.2M | $-25.1M | $-28.2M | $-30.2M | $-56.9M | $-57.3M | $-100.7M | $-45.0M | $-55.2M | $-43.8M | ||
| Gain on Sale of Securities | -- | $8.3M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-6.3M | $-24.0M | $-47.3M | $-249.5M | $-290.7M | $-436.3M | $-235.9M | $-225.2M | $-844.4M | $-1.7B | ||
| Other Special Charges | $6.3M | $24.0M | $47.3M | $249.5M | $290.7M | $436.3M | $179.3M | $225.2M | $844.4M | $1.7B | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $1.3B | $2.1B | $2.6B | $2.5B | $3.9B | $9.4B | $4.9B | $4.3B | $4.8B | $5.3B | ||
| Pre-Tax Income | $1.3B | $2.1B | $2.6B | $2.4B | $3.8B | $9.3B | $4.9B | $4.2B | $4.8B | $5.2B | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $434.3M | $880.0M | $109.1M | $313.3M | $297.2M | $1.3B | $520.4M | $245.7M | $367.3M | $725.8M | ||
| NET INCOME | ||||||||||||
| Net Income | $895.5M | $1.2B | $2.4B | $2.1B | $3.5B | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B | ||
| Net Income (Continuing Operations) | $895.5M | $1.2B | $2.4B | $2.1B | $3.5B | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B | ||
| Net Income (Discontinued Operations) | $895.5M | $1.2B | $2.4B | $2.1B | $3.5B | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B | ||
| Net Income (Common Stockholders) | $1.1B | $1.2B | $2.4B | $2.5B | $3.5B | $8.2B | $4.3B | $4.0B | $4.4B | $4.5B | ||
| Normalized Income | $864.4M | -- | $2.0B | $1.9B | $3.0B | -- | -- | -- | -- | $5.2B | ||
| TOTALS | ||||||||||||
| Total Expenses | $3.4B | $3.6B | $4.0B | $4.0B | $4.4B | $6.4B | $7.2B | $7.1B | $8.1B | $8.5B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $104.7M | $106.3M | $107.9M | $109.2M | $107.6M | $105.7M | $107.1M | $106.7M | $107.9M | $104.6M | ||
| Average Shares Outstanding (Diluted) | $116.4M | $116.0M | $114.8M | $114.6M | $115.1M | $112.2M | $113.5M | $113.7M | $115.1M | $108.6M | ||
| Shares Outstanding | $212.2M | $215.4M | $218.6M | $220.0M | $107.1M | $108.5M | $109.3M | $109.8M | $109.3M | $105.7M | ||
| Basic EPS | $8.55 | $11.27 | $22.65 | $19.38 | $32.65 | $76.4 | $40.51 | $37.05 | $40.9 | $43.07 | ||
| Basic EPS (Continuing Operations) | $8.55 | $11.27 | $22.65 | $19.38 | $32.65 | $76.4 | $40.51 | $37.05 | $40.9 | $43.07 | ||
| Diluted EPS | $7.7 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | ||
| Diluted EPS (Continuing Operations) | $7.7 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | ||
| OTHER METRICS | ||||||||||||
| Other Gand A | $1.2B | $1.3B | $1.6B | $1.3B | $1.3B | $1.8B | $2.1B | $2.6B | $3.0B | $2.7B | ||
| Rent And Landing Fees | $16.7M | $4.3M | $4.9M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | REGN | $701.42 | -0.8% | 728.88K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Regeneron Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW